Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNA7 | P36544 | 4/20 | 0.73 |
| ▸ | BCHE | P06276 | 1/20 | 0.51 |
| ▸ | ACHE | P22303 | 1/20 | 0.51 |
| ▸ | BACE1 | P56817 | 1/20 | 0.51 |
| ▸ | CHRNB4 | P30926 | 2/20 | 0.49 |
| ▸ | CHRNA3 | P32297 | 2/20 | 0.49 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.46 |
| ▸ | HTR3A | P46098 | 3/20 | 0.46 |
| ▸ | ACKR3 | P25106 | 1/20 | 0.44 |
| ▸ | CHRNA1 | P02708 | 1/20 | 0.44 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.44 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Fumaric Acid SCHEMBL2113274 | 0.90 | CHRNA7 (0.60) | CHRNA7BCHEACHEBACE1CHRNB4 | |
| SCHEMBL1395941 | 0.90 | CHRNA7 (0.73) | CHRNA7BCHEACHEBACE1CHRNB4 | |
| SCHEMBL1396005 | 0.88 | CHRNA7 (0.62) | CHRNA7BCHEACHEBACE1CHRNB4 | |
| SCHEMBL1689257 | 0.85 | CHRNA7 (0.68) | CHRNA7CHRNB4CHRNA3KCNH2HTR3A | |
| SCHEMBL1689175 | 0.84 | CHRNA7 (1.00) | CHRNA7BCHEACHEBACE1CHRNB4 | |
| SCHEMBL18016318 | 0.84 | CHRNA7 (1.00) | CHRNA7BCHEACHEBACE1CHRNB4 | |
| SCHEMBL1689172 | 0.81 | CHRNA7 (0.75) | CHRNA7CHRNB4CHRNA3KCNH2HTR3A | |
| SCHEMBL1395842 | 0.81 | CHRNA7 (0.78) | CHRNA7CHRNB4CHRNA3KCNH2HTR3A | |
| Hydrochloric Acid SCHEMBL2112287 | 0.81 | CHRNA7 (0.73) | CHRNA7CHRNB4CHRNA3KCNH2HTR3A | |
| SCHEMBL1688975 | 0.79 | CHRNA7 (0.79) | CHRNA7CHRNB4CHRNA3KCNH2HTR3A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120172353-A1 | 1,4-DIAZA-BICYCLO[3.2.2]NONYL OXADIAZOLYL COMPOUNDS AND THEIR MEDICAL USE | DANPET AB (SE) | 2012-07-05 | — | — | US | claimed |
| US-20100216780-A1 | NOVEL 1,4-DIAZA-BICYCLO[3.2.2]NONYL OXADIAZOLYL DERIVATIVES AND THEIR MEDICAL USE | DANPET AB (SE) | 2010-08-26 | — | — | US | claimed |
| EP-2032574-A1 | NOVEL 1,4-DIAZA-BICYCLO[3.2.2]NONYL OXADIAZOLYL DERIVATIVES AND THEIR MEDICAL USE | NEUROSEARCH A/S (DK) | 2009-03-11 | — | — | EP | claimed |
| WO-2007138037-A1 | NOVEL 1,4-DIAZA-BICYCLO[3.2.2]NONYL OXADIAZOLYL DERIVATIVES AND THEIR MEDICAL USE | NEUROSEARCH A/S (DK) | 2007-12-06 | — | — | WO | claimed |
| US-8372832-B2 | 1,4-diaza-bicyclo[3.2.2]nonyl oxadiazolyl compounds and their medical use | NEUROSEARCH A/S (DK) | 2013-02-12 | — | — | US | disclosed |
| US-20120172353-A1 | 1,4-DIAZA-BICYCLO[3.2.2]NONYL OXADIAZOLYL COMPOUNDS AND THEIR MEDICAL USE | DANPET AB (SE) | 2012-07-05 | — | — | US | disclosed |
| US-8158619-B2 | 1,4-diaza-bicyclo[3.2.2]nonyl oxadiazolyl compounds and their medical use | NEUROSEARCH A/S (DK) | 2012-04-17 | — | — | US | disclosed |
| US-20100216780-A1 | NOVEL 1,4-DIAZA-BICYCLO[3.2.2]NONYL OXADIAZOLYL DERIVATIVES AND THEIR MEDICAL USE | DANPET AB (SE) | 2010-08-26 | — | — | US | disclosed |
| EP-2194056-A1 | Novel 1,4-diaza-bicyclo[3.2.2]nonyl oxadiazolyl derivatives and their medical use | NeuroSearch A/S (DK) | 2010-06-09 | — | — | EP | disclosed |
| EP-2032574-A1 | NOVEL 1,4-DIAZA-BICYCLO[3.2.2]NONYL OXADIAZOLYL DERIVATIVES AND THEIR MEDICAL USE | NEUROSEARCH A/S (DK) | 2009-03-11 | — | — | EP | disclosed |
| WO-2007138037-A1 | NOVEL 1,4-DIAZA-BICYCLO[3.2.2]NONYL OXADIAZOLYL DERIVATIVES AND THEIR MEDICAL USE | NEUROSEARCH A/S (DK) | 2007-12-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100216780-A1 | NOVEL 1,4-DIAZA-BICYCLO[3.2.2]NONYL OXADIAZOLYL DERIVATIVES AND THEIR MEDICAL USE | CHRNA3, CHRNA6, CHRNA2 | CHRNA7 7/4885BCHE 69/4885ACHE 19/4885 |
| US-20120172353-A1 | 1,4-DIAZA-BICYCLO[3.2.2]NONYL OXADIAZOLYL COMPOUNDS AND THEIR MEDICAL USE | CHRNA3, CHRNA6, CHRNA2 | CHRNA7 7/4885BCHE 67/4885ACHE 15/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.